By a News Reporter-Staff News Editor at Drug Week -- Fresh data on Nanoparticles are presented in a new report. According to news reporting originating from Braunschweig, Germany, by NewsRx correspondents, research stated, "Supercooled smectic cholesteryl myristate nanoparticle dispersions, a potential carrier system for lipophilic drugs, can be stabilized with phospholipids and their mixtures with sodium glycocholate. Such dispersions are commonly prepared by high-pressure melt homogenization."
Our news editors obtained a quote from the research from Technical University, "As cholesterol esters and phospholipids are both susceptible to oxidation and hydrolysis, the chemical stability of the dispersions was studied directly after preparation and during storage. Despite the high temperatures occurring during processing, no hydrolysis was detected in the dispersions directly after preparation. During storage for 5-8 months, dispersions solely stabilized with phospholipids exhibited massive phospholipid hydrolysis as determined by HPTLC. Phospholipid hydrolysis resulted in distinct changes of the physicochemical properties such as pH, zeta potential, and phase behavior of the dispersions. In systems additionally containing sodium glycocholate as stabilizer, hydrolytic degradation occurred only to a minor extent. Phospholipid hydrolysis could also be reduced by adding TRIS-or phosphate-buffer (10mM, pH 7.4) to the aqueous phase before the preparation process. The addition of EDTA and ?-tocopherol, which were mainly employed with the aim to suppress oxidation processes, also reduced the phospholipid hydrolysis to a certain extent."
According to the news editors, the research concluded: "A partial oxidation of the cholesteryl myristate was observed in several dispersions by HPTLC, HPLC and mass spectrometry after long-term storage, but could be reduced by adding EDTA or ?-tocopherol."
For more information on this research see: Chemical stability of phospholipid-stabilized supercooled smectic cholesteryl myristate nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2012;82(2):262-71. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.elsevier.com/wps/product/cws_home/600120)
The news editors report that additional information may be obtained by contacting F. Mengersen, Technische Universitat Braunschweig, Institut fur Pharmazeutische Technologie, Mendelssohnstraße 1, Braunschweig, Germany. Additional authors for this research include H. Bunjes (see also Nanoparticles).
Keywords for this news article include: Europe, Germany, Braunschweig, Nanotechnology, Emerging Technologies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC